论文信息 - A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer. - 字舞流文

A phase 1b trial of PI3K inhibitor copanlisib (BAY 80-6946) combined with the allosteric-MEK inhibitor refametinib (BAY 86-9766) in patients with advanced cancer.

P. Rajagopalan | G. Blumenschein | D. Richards | D. D. Hoff | C. Peña | F. Eskens | K. Mross | F. Renshaw | R. Ramanathan | A. Kelly